Literature DB >> 10072510

Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma.

J White1, F Crawford, D Fremont, P Marrack, J Kappler.   

Abstract

Soluble forms of the mouse MHC class I molecule, Dd, were produced in which the peptide binding groove was uniformly occupied by peptides attached via a covalent flexible peptide linker to the N terminus of the associated beta2-microglobulin. The MHC heavy chain and beta2-microglobulin were firmly associated, and the molecules displayed an Ab epitope requiring proper occupancy of the peptide binding groove. Soluble Dd containing a covalent version of a well-characterized Dd-binding peptide from HIV stimulated a T cell hybridoma specific for this combination. Furthermore, a tetravalent version of this molecule bound specifically with apparent high avidity to this hybridoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072510

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Properties and applications of single-chain major histocompatibility complex class I molecules.

Authors:  Eleni Kotsiou; Joanna Brzostek; Keith G Gould
Journal:  Antioxid Redox Signal       Date:  2011-03-31       Impact factor: 8.401

2.  Using a baculovirus display library to identify MHC class I mimotopes.

Authors:  Yibing Wang; Anatoyla Rubtsov; Ryan Heiser; Janice White; Frances Crawford; Philippa Marrack; John W Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

3.  An efficient and versatile mammalian viral vector system for major histocompatibility complex class I/peptide complexes.

Authors:  Ai Kawana-Tachikawa; Mariko Tomizawa; Jun-Ichi Nunoya; Tatsuo Shioda; Atsushi Kato; Emi E Nakayama; Tetsuya Nakamura; Yoshiyuki Nagai; Aikichi Iwamoto
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 4.  Basic and translational applications of engineered MHC class I proteins.

Authors:  Ted H Hansen; Janet M Connolly; Keith G Gould; Daved H Fremont
Journal:  Trends Immunol       Date:  2010-09-09       Impact factor: 16.687

5.  TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines.

Authors:  Kimberly R Jordan; Jonathan D Buhrman; Jonathan Sprague; Brandon L Moore; Dexiang Gao; John W Kappler; Jill E Slansky
Journal:  Cancer Immunol Immunother       Date:  2012-02-21       Impact factor: 6.968

6.  L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart.

Authors:  Daniela Cihakova; Jobert G Barin; G Christian Baldeviano; Miho Kimura; Monica V Talor; Daniel H Zimmerman; Eyal Talor; Noel R Rose
Journal:  Int Immunopharmacol       Date:  2008-01-29       Impact factor: 4.932

7.  Expression and characterization of soluble epitope-defined major histocompatibility complex (MHC) from stable eukaryotic cell lines.

Authors:  Amanda L Wooster; Trevor S Anderson; Devin B Lowe
Journal:  J Immunol Methods       Date:  2018-10-19       Impact factor: 2.303

8.  Antigen-activated dendritic cells ameliorate influenza A infections.

Authors:  Kobporn Boonnak; Leatrice Vogel; Marlene Orandle; Daniel Zimmerman; Eyal Talor; Kanta Subbarao
Journal:  J Clin Invest       Date:  2013-06-24       Impact factor: 14.808

9.  T cells compete for access to antigen-bearing antigen-presenting cells.

Authors:  R M Kedl; W A Rees; D A Hildeman; B Schaefer; T Mitchell; J Kappler; P Marrack
Journal:  J Exp Med       Date:  2000-10-16       Impact factor: 14.307

10.  T cell receptor (TCR)-mediated repertoire selection and loss of TCR vbeta diversity during the initiation of a CD4(+) T cell response in vivo.

Authors:  M Fassò; N Anandasabapathy; F Crawford; J Kappler; C G Fathman; W M Ridgway
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.